论文部分内容阅读
目的 研究用脐血单个核细胞制备CD3AK细胞的抗肿瘤作用,探讨肿瘤生物治疗近期疗效的免疫指标。方法 分离脐血单个核细胞,分别用IL-2和IL-2+CD3Ab诱导LAK和CD_3AK细胞,并测其扩增数量和对K562细胞的杀伤活性;测定肿瘤患者用CD3AK细胞治疗前、后外周血单核细胞(PBMC)的NK杀伤活性。结果 脐血LAK细胞和脐血CD3AK细胞均于培养后d11时扩增倍数最高,分别是培养前的18倍、24倍,对K562的杀伤活性分别是培养前的2.6倍和3.2倍;肿瘤患者输注CD3AK细胞1疗程后,其PBMC的NK杀伤活性由63％升高到81％,平均升高28％。结论(1)脐血单个核细胞是LAK细胞和CD3AK细胞良好的前体细胞。(2)LAK和CD3AK细胞的数量和杀伤能力在培养的d11时达高峰,而且CD3AK细胞数量和杀伤活性明显优于LAK细胞。(3)CD3AK细胞输注能明显提高肿瘤患者PBMC的NK活性。(4)肿瘤病人PBMC的NK活性测定可望成为肿瘤生物治疗的一个近期疗效参数。
Objective To study the antitumor effect of CD3AK cells prepared from cord blood mononuclear cells and to explore the immunological parameters of tumor biological therapy in the near future. Methods Umbilical cord blood mononuclear cells were isolated and induced by IL-2 and IL-2 + CD3Ab respectively. The proliferation of K562 cells and LAK and CD3AK cells were measured. The numbers of CD3AK cells in peripheral blood NK cytotoxic activity of blood mononuclear cells (PBMCs). Results Both umbilical cord blood LAK cells and umbilical cord blood CD3AK cells had the highest fold expansion at d11 after culture, which were 18-fold and 24-fold, respectively. The cytotoxicity against K562 was 2.6-fold and 3.2-fold higher than that before culturing respectively. After one course of CD3AK cells infusion, the NK cytotoxic activity of PBMC increased from 63% to 81% with an average increase of 28%. Conclusion (1) Cord blood mononuclear cells are good precursors of LAK cells and CD3AK cells. (2) The number and cytotoxicity of LAK and CD3AK cells peaked at day 11 of culture, and the number and cytotoxic activity of CD3AK cells were significantly better than that of LAK cells. (3) CD3AK cell infusion can significantly improve the NK activity of PBMC in cancer patients. (4) The determination of NK activity of PBMC in tumor patients is expected to become a near-term therapeutic parameter of tumor biological therapy.